Anti-FZD10 monoclonal antibodies and methods for their use
The present invention relates generally to anti-FZD10 antibodies and to methods of using anti-FZD10 antibodies. In particular, the anti-FZD10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of FZD10, including as stand-alone therapies and in combination therapies with other agents.
1. A composition comprising an isolated anti-FZD10 antibody that is selected from the group consisting of:
(a) an isolated antibody, or an antigen-binding fragment thereof, that binds to human FZD10, comprising a heavy chain variable region comprising the VHCDR1, VHCDR2 and VHCDR3 amino acid sequences set forth in SEQ ID NOs:5, 6 and 7, respectively, and a light chain variable region comprising the VLCDR1, VLCDR2 and VLCDR3 amino acid sequences set forth in: SEQ ID NOs:9, 11, 12, respectively, or SEQ ID NOs:10, 11, 12, respectively;
(b) the isolated antibody, or an antigen-binding fragment thereof, of (a), wherein the heavy chain variable region comprises the VHCDR1, VHCDR2 and VHCDR3amino acid sequences set forth in SEQ ID NOs:5, 6, and 7, respectively, and the light chain variable region comprises the VLCDR1, VLCDR2 and VLCDR3 amino acid sequences set forth in SEQ ID NOs:9, 11, and 12, respectively;
(c) the isolated antibody, or an antigen-binding fragment thereof, of (b), wherein he light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:3;
(d) the isolated antibody, or an antigen-binding fragment thereof, of (b), wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:1;
(e) the isolated antibody, or an antigen-binding fragment thereof, of (a), wherein the heavy chain variable region comprises the VHCDR1, VHCDR2 and VHCDR3 amino acid sequences set forth in SEQ ID) NOs:5, 6, and 7, respectively, and the light chain variable region comprises the VLCDR1, VLCDR2 and VLCDR3 amino acid sequences set forth in SEQ ID NOs:10, 11, and 12, respectively;
(f) the isolated antibody, or an antigen-binding fragment thereof, of (e), wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:1;
(g) the isolated antibody, or an antigen-binding fragment thereof, of (e), wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:4;
(h) the isolated antibody, or an antigen-binding fragment thereof, of (a) wherein the antibody is humanized;
(i) the isolated antibody, or antigen-binding fragment thereof, of (h) wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:37;
(j) the isolated antibody, or antigen-binding fragment thereof, of (i), further comprising a heavy chain variable region that comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ NO:39;
(k) the isolated antibody, or antigen-binding fragment thereof, of (i), further comprising a heavy chain variable region that comprises the amino acid sequence set forth in SEQ ID NO:39;
(l) the isolated antibody, or antigen-binding fragment thereof, of (k), further comprising a human lambda light chain constant region comprising the amino acid sequence set forth in SEQ ID NO:36;
(m) the isolated antibody, or antigen-binding fragment thereof, of (l), further comprising a human IgGl constant region comprising the amino acid sequence set forth in SEQ ID NO:34; and
(n) the isolated antibody, or antigen-binding fragment thereof, of (h), wherein the isolated antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO:29 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:31,
2. The composition of claim 1 wherein the isolated anti-FZD 10 antibody is selected from the group consisting of (i) a single chain antibody, a ScFv, a univalent antibody lacking a hinge region, or a minibody; (ii) a Fab, Fab′ or F(ab′) 2 fragment; (iii) a whole antibody; (iv) an antibody that comprises a human IgG Fe domain; and (v) the antibody of (iv) wherein the human IgG Fc domain is modified to obtain a modified antibody that has enhanced ADCC activity as compared to the antibody in which the human IgG Fc domain has not been modified.
3. The composition of claim 1 wherein the isolated anti-FZD10 antibody is conjugated to a drug or a toxin.
4. The composition of claim 3 wherein the toxin is saporin.
5. The composition of claim 1 in which the isolated anti-FZD10 antibody, or an antigen-binding fragment thereof, that binds to human FZD10, comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:1.
6. The composition of claim 5 in which the anti-FZD10 antibody further comprises (i) a light chain variable region comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO:3; (ii) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:3; (iii) a light chain variable region comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO:4; or (iv) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:4.
7. The composition of claim 5 wherein the anti-FZD10 antibody further comprises (i) a light chain variable region comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO:2; or (ii) a light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO:2.
8. The composition of claim 5 wherein the isolated anti-FZD10 antibody is selected from the group consisting of: (i) a single chain antibody, a ScFv, a univalent antibody lacking a hinge region or a minibody; (ii) a Fab, Fab′ or F(ab′) 2 fragment; (iii) a whole antibody; (iv) an antibody that comprises a human IgG Fc domain; and (v) the antibody of (iv) wherein the human IgG Fc domain is modified to obtain a modified antibody that has enhanced ADCC activity as compared to the antibody in which the human IgG Fc domain has not been modified.
9. An isolated anti-FZD10 antibody, or an antigen-binding fragment thereof, that binds to human FZD-10, comprising
(a) a light chain variable region comprising the VLCDR1, VLCDR2 and VLCDR3 amino acid sequences set forth in SEQ ID NO:s 9, 11, 12, respectively, or SEQ. ID) NOs:10, 11, 12 respectively; and
(b) a heavy chain variable region comprises the VHCDR1, VHCDR2 and VHCDR3 amino acid sequences set forth in SEQ ID NO:s 5, 6 and 7, respectively.
10. The anti-FZD10 antibody of claim 9 , wherein said antibody is selected from the group consisting of: (i) a single chain antibody, a ScFv, a univalent antibody lacking a hinge region or a minibody, (ii) a Fab, Fab′ or F(ab′), fragment; (iii) a whole antibody; (iv) an antibody that comprises a human IgG Fc domain; and (v) the antibody of (iv) wherein the human IgG Fc domain is modified to obtain a modified antibody that has enhanced ADCC activity as compared to the antibody in which the human IgG Fc domain has not been modified.
11. The antibody of claim 9 wherein the isolated anti-FZD10 antibody is conjugated to a drug or a toxin.
12. The antibody of claim 11 wherein the toxin is saporin.
13. The composition of claim 1 which further comprises a physiologically acceptable carrier.
14. The composition of claim 1 , wherein the isolated anti-FZD10 antibody, or antigen-binding fragment thereof, is conjugated to a detectable moiety.
15. The isolated anti-FZD10 antibody, or antigen-binding fragment thereof, of claim 9 , wherein the antibody or antibody-binding fragment is conjugated to a detectable moiety.
16. The isolated antibody or antigen-binding fragment thereof of claim 9 , wherein the antibody or antigen-binding fragment thereof is humanized.
17. The isolated antibody or antigen-binding fragment thereof of claim 16 , wherein the antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:37.
18. The isolated antibody or antigen-binding fragment thereof of claim 16 , wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:39.
19. The isolated antibody of claim 16 , wherein the antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO:29 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:31.